Anthem Biosciences IPO: 12% GMP Creates Investor Frenzy in Pharma Sector
By MoneyCal Editorial Team • Published 2026
Anthem Biosciences has captured significant investor attention with its IPO generating a robust 12% Grey Market Premium, reflecting strong confidence in the pharmaceutical sector and the company's specialized bioscience capabilities. As India's pharmaceutical industry continues its global expansion and innovation drive, specialized players like Anthem Biosciences are positioned to benefit from the sector's growth trajectory.